How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    a. Has all of the relevant evidence been taken into account?

  • Question on Consultation

    b. Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    c. Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    d. Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

2 Information about beremagene geperpavec

Marketing authorisation indication

2.1

Beremagene geperpavec (Vyjuvek, Krystal Biotech) is indicated for 'the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene, from birth'.

Dosage in the marketing authorisation

Price

2.3

The list price is £21,500 per 1-ml vial of beremagene geperpavec, providing 4 extractable 0.5-ml doses when prepared (excluding VAT; company submission).

2.4

The company has a commercial arrangement (simple discount patient access scheme). This makes beremagene geperpavec available to the NHS with a discount and it would have also applied to this indication if beremagene geperpavec had been recommended. The size of the discount is commercial in confidence.

Sustainability

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Krystal Biotech will be included here when guidance is published.